Healthcare / BiotechnologyKOSDAQ
$31700.00
+1150.00 (+3.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $63.1B · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.44T
P/E
30.3x
↑EV/EBITDA
10.4x
↓ROE
4.8%
↑Gross Margin
64.1%
↑Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-17.8%
FCF CAGR
-23.9%
FCF margin
23.0%
FCF / Net income
2.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $474.23B · net income $48.27B · FCF $108.87B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $474.23B | $474.23B | $414.25B | $367.38B | $853.56B |
| Net Income | $48.27B | $48.27B | $-8.76B | $669.0M | $182.14B |
| EBITDA | $130.91B | $130.91B | $67.54B | $70.02B | $288.53B |
| EPS | 1047.00 | 1047.00 | -190.00 | 14.00 | 3586.00 |
| Gross Margin | 64.1% | 64.1% | 57.6% | 57.7% | 58.1% |
| Operating Margin | 7.3% | 7.3% | -4.0% | -8.2% | 23.0% |
| Net Margin | 10.2% | 10.2% | -2.1% | 0.2% | 21.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.15 | 0.14 | 0.14 |
| Current Ratio | 4.46 | 4.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $108.87B | $108.87B | $41.76B | $63.05B | $246.56B |
| Returns | |||||
| ROE | 4.8% | 4.8% | -0.9% | 0.1% | 15.9% |
| Valuation | |||||
| P/E | 30.28 | 30.28 | — | 1667.86 | 7.74 |
| EV/EBITDA | 10.43 | 10.43 | 14.66 | 15.24 | 3.63 |
| P/B | 1.44 | 1.44 | 1.12 | 1.09 | 1.23 |
| Growth & Yield | |||||
| Revenue Growth | 14.5% | 14.5% | 12.8% | -57.0% | — |
| EPS Growth | 651.1% | 651.1% | -1457.1% | -99.6% | — |
| Dividend Yield | 3.9% | 3.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
39.0%
EPS terminal req.
$2812.85
Spread vs growth
612.0%
5Y implied EPS CAGR
26.6%
EPS terminal req.
$3403.54
Spread vs growth
624.5%
10Y implied EPS CAGR
18.0%
EPS terminal req.
$5481.44
Spread vs growth
633.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-190.00 → 1047.00
Residual
+1.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.